State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

State Street Corp grew its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 5.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 469,601 shares of the company’s stock after acquiring an additional 24,385 shares during the quarter. State Street Corp owned 1.25% of Entrada Therapeutics worth $7,504,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. US Bancorp DE bought a new stake in Entrada Therapeutics during the 3rd quarter worth approximately $42,000. SG Americas Securities LLC bought a new stake in shares of Entrada Therapeutics during the third quarter worth $156,000. Acadian Asset Management LLC raised its holdings in shares of Entrada Therapeutics by 135.1% during the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock worth $190,000 after acquiring an additional 7,682 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Entrada Therapeutics by 34.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after acquiring an additional 3,644 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Entrada Therapeutics by 87.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock worth $394,000 after purchasing an additional 12,868 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA opened at $17.41 on Friday. The stock has a 50 day moving average price of $18.53 and a 200 day moving average price of $16.74. The stock has a market capitalization of $651.48 million, a PE ratio of 10.95 and a beta of -0.18. Entrada Therapeutics, Inc. has a 52 week low of $11.35 and a 52 week high of $21.79.

Analysts Set New Price Targets

TRDA has been the topic of a number of research reports. Oppenheimer boosted their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Roth Mkm started coverage on Entrada Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $29.00 target price on the stock. HC Wainwright raised their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th.

Insider Transactions at Entrada Therapeutics

In other news, CFO Kory James Wentworth sold 5,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the chief financial officer now directly owns 73,849 shares in the company, valued at $1,476,980. The trade was a 6.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Natarajan Sethuraman sold 1,409 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $20.01, for a total transaction of $28,194.09. Following the completion of the sale, the insider now owns 163,588 shares of the company’s stock, valued at $3,273,395.88. This trade represents a 0.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,281 shares of company stock worth $861,999 in the last 90 days. Corporate insiders own 7.59% of the company’s stock.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.